Adenovector Efficiency: Increased Transduction VLI has developed technology to modify the adenovector outer coat proteins for the increased transduction of tumor cells. Efficiency of transduction is a major determinant of the eventual effectiveness of a vector for clinical use. VLI's lead product is a transduction-enhanced, conditionally replicative adenovector (CRAd)  to treat solid tumors. This vector can effectively destroy solid tumors, largely because it can deliver its payload to cancer cells much more effectively than unmodified first generation adenovectors used previously in clinical trials. This means that VLI's transduction enhanced vectors can be used to treat cancers such as ovarian, pancreatic, colorectal and prostate, which have not been effectively treatable with first generation adenovectors. Cancer Virotherapeutics   CRAd: Tumor-specific cell killing via a Conditionally Replicative Adenovirus       Adenovector Safety: Genetic Specificity Specific modifications to the adenovector genes allows for the recognition of the status of a specific cell type. Since most aggressive cancers carry specific mutations, adenovectors with these types of genetic elements can recognize cancerous tissue. VectorLogics' lead product is a transduction-enhanced, conditionally replicative adenovector that is able to discriminate between cancer specific and normal cells for a more effective cancer treatment with fewer side effects. The incorporation of cancer-specific genetic entities enables VLI product candidates to be highly specific to cancer and so reduce toxicity and damage to healthy tissue. These features clearly distinguish the vector approach from a traditional cytotoxic therapy.